Mesa Laboratories (NASDAQ:MLAB) CEO Acquires $800,090.40 in Stock

Posted by Geri Gentry on Aug 20th, 2026

Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) CEO Siddhartha Kadia purchased 7,093 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was purchased at an average price of $112.80 per share, for a total transaction of $800,090.40. Following the completion of the acquisition, the chief executive officer owned 7,093 shares of the company’s stock, valued at approximately $800,090.40. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Mesa Laboratories Stock Up 10.9%

NASDAQ:MLAB opened at $119.72 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.32 and a current ratio of 1.79. The company has a market cap of $670.43 million, a PE ratio of 142.53 and a beta of 0.92. Mesa Laboratories, Inc. has a 52-week low of $58.83 and a 52-week high of $120.45. The stock has a 50-day simple moving average of $100.85 and a 200 day simple moving average of $96.75.

Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last announced its earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. The business had revenue of $60.14 million for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be issued a $0.16 dividend. The ex-dividend date is Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.5%. Mesa Laboratories’s dividend payout ratio (DPR) is 76.19%.

Institutional Investors Weigh In On Mesa Laboratories

Institutional investors and hedge funds have recently modified their holdings of the company. Boston Partners lifted its stake in Mesa Laboratories by 86.6% in the 4th quarter. Boston Partners now owns 213,376 shares of the medical instruments supplier’s stock valued at $16,752,000 after purchasing an additional 99,019 shares during the last quarter. Ranger Investment Management L.P. acquired a new position in Mesa Laboratories during the second quarter worth approximately $17,321,000. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Mesa Laboratories in the second quarter valued at approximately $15,507,000. Royce & Associates LP raised its stake in Mesa Laboratories by 3.2% in the fourth quarter. Royce & Associates LP now owns 153,352 shares of the medical instruments supplier’s stock valued at $12,038,000 after buying an additional 4,794 shares during the period. Finally, Kennedy Capital Management LLC lifted its position in shares of Mesa Laboratories by 19.0% in the fourth quarter. Kennedy Capital Management LLC now owns 144,606 shares of the medical instruments supplier’s stock valued at $11,352,000 after buying an additional 23,060 shares during the last quarter. 90.60% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wells Fargo & Company increased their target price on shares of Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Wall Street Zen lowered shares of Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat, Mesa Laboratories presently has a consensus rating of “Hold” and an average target price of $110.00.

Get Our Latest Stock Report on MLAB

Mesa Laboratories Company Profile

(Get Free Report)

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.